RecruitingPhase 2NCT06751784

Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression


Sponsor

University of Basel

Enrollment

38 participants

Start Date

May 22, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild to moderate depression


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether fampridine — a drug normally used for multiple sclerosis — can improve working memory and thinking skills in people with mild to moderate depression. The trial uses a cross-over design, meaning participants try both the drug and a placebo at different times. **You may be eligible if...** - You are 18–55 years old - You have a confirmed mild to moderate depressive episode (not severe) - Your blood pressure is in the normal range (or well-controlled with medication) - You are fluent in German - Your BMI is between 19 and 34.9 **You may NOT be eligible if...** - You have taken antidepressants or antipsychotics in the past 3 months - You have a history of seizures or conditions that lower the seizure threshold - You have significant kidney problems, heart issues (slow heart rate), or a history of cancer - You have another psychiatric condition such as psychosis, alcohol/drug use disorder, or severe cognitive impairment - You have difficulty walking due to dizziness Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFampridine SR

Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.

OTHERPlacebo

no active substance


Locations(1)

University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences

Basel, Canton of Basel-City, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06751784


Related Trials